We have completed our clinical trial for cerebral palsy at our clinical research center in Monterrey, Mexico. The Mexican regulatory authority COFEPRIS (equivalent to the US FDA) has acknowledged our clinical trial results and approved our protocol for cerebral palsy.
In addition to our COFEPRIS-approved protocol for cerebral palsy, we continue conducting research on protocols for other neurological conditions, with a primary focus on autism, stroke, traumatic brain injury, vascular dementia, and the neurological impacts of COVID-19.
If you are interested in finding out whether you are eligible for our protocols, please complete the eligibility form, and our team will contact you. Our clinical research center operates exclusively in Monterrey, Mexico until further regulatory approvals are secured (e.g., FDA, EMA, or similar authorities in other regions).
NeuroCytonix Mexico Clinical Research Center #
Discover the future of medical research at our state-of-the-art clinical research center.
